Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-Current Assets: 2015-2025

Historic Non-Current Assets for Spyre Therapeutics (SYRE) over the last 9 years, with Mar 2025 value amounting to $10,000.

  • Spyre Therapeutics' Non-Current Assets fell 96.96% to $10,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $10,000, marking a year-over-year decrease of 96.96%. This contributed to the annual value of $10,000 for FY2024, which is 96.98% down from last year.
  • Spyre Therapeutics' Non-Current Assets amounted to $10,000 in Q1 2025, which was down 0.00% from $10,000 recorded in Q4 2024.
  • Spyre Therapeutics' Non-Current Assets' 5-year high stood at $12.6 million during Q2 2021, with a 5-year trough of $10,000 in Q3 2024.
  • Its 3-year average for Non-Current Assets is $1.6 million, with a median of $331,000 in 2024.
  • In the last 5 years, Spyre Therapeutics' Non-Current Assets climbed by 16.03% in 2021 and then slumped by 99.24% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Non-Current Assets (Quarterly) stood at $11.0 million in 2021, then decreased by 19.47% to $8.9 million in 2022, then crashed by 96.28% to $331,000 in 2023, then plummeted by 96.98% to $10,000 in 2024, then slumped by 96.96% to $10,000 in 2025.
  • Its Non-Current Assets stands at $10,000 for Q1 2025, versus $10,000 for Q4 2024 and $10,000 for Q3 2024.